The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a
traditional Chinese herbal medicine, on cognition, function and memory in patients with
amnestic mild cognitive impairment (MCI) who are at greater risk for developing Alzheimer's
disease, in a 6-month supervised protocol of a traditional Chinese herbal medicine. The
results of this study may provide support for a relatively simple and inexpensive treatment
strategy with herbal therapy that specifically targets individuals with the mild cognitive
impairment that directly influence risk of developing dementia for older adults.